Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis.

Brownlee WJ, Altmann DR, Prados F, Miszkiel KA, Eshaghi A, Gandini Wheeler-Kingshott CAM, Barkhof F, Ciccarelli O.

Brain. 2019 Aug 1;142(8):2276-2287. doi: 10.1093/brain/awz156.

PMID:
31342055
2.

Single-subject structural cortical networks in clinically isolated syndrome.

Collorone S, Prados F, Hagens MH, Tur C, Kanber B, Sudre CH, Lukas C, Gasperini C, Oreja-Guevara C, Andelova M, Ciccarelli O, Wattjes MP, Ourselin S, Altmann DR, Tijms BM, Barkhof F, Toosy AT; MAGNIMS Study Group.

Mult Scler. 2019 Jul 24:1352458519865739. doi: 10.1177/1352458519865739. [Epub ahead of print]

3.

A multi-shell multi-tissue diffusion study of brain connectivity in early multiple sclerosis.

Tur C, Grussu F, Prados F, Charalambous T, Collorone S, Kanber B, Cawley N, Altmann DR, Ourselin S, Barkhof F, Clayden JD, Toosy AT, Wheeler-Kingshott CAG, Ciccarelli O.

Mult Scler. 2019 May 10:1352458519845105. doi: 10.1177/1352458519845105. [Epub ahead of print]

PMID:
31074686
4.

Clinical relevance of cortical network dynamics in early primary progressive MS.

Tur C, Kanber B, Eshaghi A, Altmann DR, Khaleeli Z, Prados F, Ourselin S, Thompson AJ, Gandini Wheeler-Kingshott CA, Toosy AT, Ciccarelli O.

Mult Scler. 2019 Feb 25:1352458519831400. doi: 10.1177/1352458519831400. [Epub ahead of print]

5.

Structural cortical network reorganization associated with early conversion to multiple sclerosis.

Tur C, Eshaghi A, Altmann DR, Jenkins TM, Prados F, Grussu F, Charalambous T, Schmidt A, Ourselin S, Clayden JD, Wheeler-Kingshott CAMG, Thompson AJ, Ciccarelli O, Toosy AT.

Sci Rep. 2018 Jul 16;8(1):10715. doi: 10.1038/s41598-018-29017-1.

6.

Deep gray matter volume loss drives disability worsening in multiple sclerosis.

Eshaghi A, Prados F, Brownlee WJ, Altmann DR, Tur C, Cardoso MJ, De Angelis F, van de Pavert SH, Cawley N, De Stefano N, Stromillo ML, Battaglini M, Ruggieri S, Gasperini C, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Vrenken H, Leurs CE, Killestein J, Pirpamer L, Enzinger C, Ourselin S, Wheeler-Kingshott CAMG, Chard D, Thompson AJ, Alexander DC, Barkhof F, Ciccarelli O; MAGNIMS study group.

Ann Neurol. 2018 Feb;83(2):210-222. doi: 10.1002/ana.25145. Epub 2018 Feb 6.

7.

Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis.

Afolabi D, Albor C, Zalewski L, Altmann DR, Baker D, Schmierer K.

Mult Scler. 2018 Oct;24(11):1461-1468. doi: 10.1177/1352458517726380. Epub 2017 Aug 17.

8.

Neuronal loss, demyelination and volume change in the multiple sclerosis neocortex.

Carassiti D, Altmann DR, Petrova N, Pakkenberg B, Scaravilli F, Schmierer K.

Neuropathol Appl Neurobiol. 2018 Jun;44(4):377-390. doi: 10.1111/nan.12405. Epub 2017 Jun 1.

9.

FLAIR* to visualize veins in white matter lesions: A new tool for the diagnosis of multiple sclerosis?

Campion T, Smith RJP, Altmann DR, Brito GC, Turner BP, Evanson J, George IC, Sati P, Reich DS, Miquel ME, Schmierer K.

Eur Radiol. 2017 Oct;27(10):4257-4263. doi: 10.1007/s00330-017-4822-z. Epub 2017 Apr 13.

10.

Axonal loss in the multiple sclerosis spinal cord revisited.

Petrova N, Carassiti D, Altmann DR, Baker D, Schmierer K.

Brain Pathol. 2018 May;28(3):334-348. doi: 10.1111/bpa.12516. Epub 2017 May 7.

11.

Reduced Field-of-View Diffusion-Weighted Imaging of the Lumbosacral Enlargement: A Pilot In Vivo Study of the Healthy Spinal Cord at 3T.

Yiannakas MC, Grussu F, Louka P, Prados F, Samson RS, Battiston M, Altmann DR, Ourselin S, Miller DH, Gandini Wheeler-Kingshott CA.

PLoS One. 2016 Oct 14;11(10):e0164890. doi: 10.1371/journal.pone.0164890. eCollection 2016.

12.

Periventricular lesions and MS diagnostic criteria in young adults with typical clinically isolated syndromes.

Brownlee WJ, Miszkiel KA, Altmann DR, Ciccarelli O, Miller DH.

Mult Scler. 2017 Jun;23(7):1031-1034. doi: 10.1177/1352458516667565. Epub 2016 Sep 6.

13.

Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome.

Brownlee WJ, Altmann DR, Alves Da Mota P, Swanton JK, Miszkiel KA, Wheeler-Kingshott CG, Ciccarelli O, Miller DH.

Mult Scler. 2017 Apr;23(5):665-674. doi: 10.1177/1352458516663034. Epub 2016 Aug 6.

14.

Phenytoin for neuroprotection - Authors' reply.

Kapoor R, Raftopoulos R, Altmann DR, Miller DH, Hickman SJ.

Lancet Neurol. 2016 Aug;15(9):902-903. doi: 10.1016/S1474-4422(16)30094-1. No abstract available.

PMID:
27478948
15.

Longitudinal evidence for anterograde trans-synaptic degeneration after optic neuritis.

Tur C, Goodkin O, Altmann DR, Jenkins TM, Miszkiel K, Mirigliani A, Fini C, Gandini Wheeler-Kingshott CA, Thompson AJ, Ciccarelli O, Toosy AT.

Brain. 2016 Mar;139(Pt 3):816-28. doi: 10.1093/brain/awv396. Epub 2016 Feb 17.

16.

Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial.

Raftopoulos R, Hickman SJ, Toosy A, Sharrack B, Mallik S, Paling D, Altmann DR, Yiannakas MC, Malladi P, Sheridan R, Sarrigiannis PG, Hoggard N, Koltzenburg M, Gandini Wheeler-Kingshott CA, Schmierer K, Giovannoni G, Miller DH, Kapoor R.

Lancet Neurol. 2016 Mar;15(3):259-69. doi: 10.1016/S1474-4422(16)00004-1. Epub 2016 Jan 26.

PMID:
26822749
17.

Fully automated segmentation of the cervical cord from T1-weighted MRI using PropSeg: Application to multiple sclerosis.

Yiannakas MC, Mustafa AM, De Leener B, Kearney H, Tur C, Altmann DR, De Angelis F, Plantone D, Ciccarelli O, Miller DH, Cohen-Adad J, Gandini Wheeler-Kingshott CA.

Neuroimage Clin. 2015 Nov 10;10:71-7. doi: 10.1016/j.nicl.2015.11.001. eCollection 2016.

18.

White and gray matter damage in primary progressive MS: The chicken or the egg?

Bodini B, Chard D, Altmann DR, Tozer D, Miller DH, Thompson AJ, Wheeler-Kingshott C, Ciccarelli O.

Neurology. 2016 Jan 12;86(2):170-6. doi: 10.1212/WNL.0000000000002237. Epub 2015 Dec 16.

19.

No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.

Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, Juliusson G, Baker D, Chataway J, Schmierer K.

Neurol Neuroimmunol Neuroinflamm. 2015 Oct 1;2(6):e158. doi: 10.1212/NXI.0000000000000158. eCollection 2015 Dec.

20.

Grey matter involvement by focal cervical spinal cord lesions is associated with progressive multiple sclerosis.

Kearney H, Miszkiel KA, Yiannakas MC, Altmann DR, Ciccarelli O, Miller DH.

Mult Scler. 2016 Jun;22(7):910-20. doi: 10.1177/1352458515604905. Epub 2015 Oct 2.

21.

Motor network efficiency and disability in multiple sclerosis.

Pardini M, Yaldizli Ö, Sethi V, Muhlert N, Liu Z, Samson RS, Altmann DR, Ron MA, Wheeler-Kingshott CA, Miller DH, Chard DT.

Neurology. 2015 Sep 29;85(13):1115-22. doi: 10.1212/WNL.0000000000001970. Epub 2015 Aug 28.

22.

Sample sizes for lesion magnetisation transfer ratio outcomes in remyelination trials for multiple sclerosis.

Altmann DR, Button T, Schmierer K, Hunter K, Tozer DJ, Wheeler-Kingshott CA, Coles A, Miller DH.

Mult Scler Relat Disord. 2014 Mar;3(2):237-43. doi: 10.1016/j.msard.2013.09.007. Epub 2013 Oct 9.

PMID:
25878011
23.

Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosis.

Abdel-Aziz K, Schneider T, Solanky BS, Yiannakas MC, Altmann DR, Wheeler-Kingshott CA, Peters AL, Day BL, Thompson AJ, Ciccarelli O.

Brain. 2015 Jun;138(Pt 6):1568-82. doi: 10.1093/brain/awv086. Epub 2015 Apr 10.

24.

Cervical cord lesion load is associated with disability independently from atrophy in MS.

Kearney H, Altmann DR, Samson RS, Yiannakas MC, Wheeler-Kingshott CA, Ciccarelli O, Miller DH.

Neurology. 2015 Jan 27;84(4):367-73. doi: 10.1212/WNL.0000000000001186. Epub 2014 Dec 24.

PMID:
25540312
25.

Earlier and more frequent diagnosis of multiple sclerosis using the McDonald criteria.

Brownlee WJ, Swanton JK, Altmann DR, Ciccarelli O, Miller DH.

J Neurol Neurosurg Psychiatry. 2015 May;86(5):584-5. doi: 10.1136/jnnp-2014-308675. Epub 2014 Nov 20. No abstract available.

26.

Age related changes in metabolite concentrations in the normal spinal cord.

Abdel-Aziz K, Solanky BS, Yiannakas MC, Altmann DR, Wheeler-Kingshott CA, Thompson AJ, Ciccarelli O.

PLoS One. 2014 Oct 13;9(10):e105774. doi: 10.1371/journal.pone.0105774. eCollection 2014.

27.

HLA-DRB1*15 influences the development of brain tissue damage in early PPMS.

Tur C, Ramagopalan S, Altmann DR, Bodini B, Cercignani M, Khaleeli Z, Miller DH, Thompson AJ, Ciccarelli O.

Neurology. 2014 Nov 4;83(19):1712-8. doi: 10.1212/WNL.0000000000000959. Epub 2014 Oct 8.

28.

Spinal cord grey matter abnormalities are associated with secondary progression and physical disability in multiple sclerosis.

Kearney H, Schneider T, Yiannakas MC, Altmann DR, Wheeler-Kingshott CA, Ciccarelli O, Miller DH.

J Neurol Neurosurg Psychiatry. 2015 Jun;86(6):608-14. doi: 10.1136/jnnp-2014-308241. Epub 2014 Aug 5.

PMID:
25097217
29.

Cerebral arterial bolus arrival time is prolonged in multiple sclerosis and associated with disability.

Paling D, Thade Petersen E, Tozer DJ, Altmann DR, Wheeler-Kingshott CA, Kapoor R, Miller DH, Golay X.

J Cereb Blood Flow Metab. 2014 Jan;34(1):34-42. doi: 10.1038/jcbfm.2013.161. Epub 2013 Sep 18.

30.

Prevalence of severely impaired left ventricular ejection fraction after reperfused ST-elevation myocardial infarction.

Altmann DR, Mutschelknauss M, Ehl N, Koller M, Schaer B, Jörg L, Ammann P, Kühne M, Rickli H, Osswald S, Sticherling C.

Swiss Med Wkly. 2013 Sep 6;143:w13869. doi: 10.4414/smw.2013.13869. eCollection 2013.

31.

MRI investigation of the sensorimotor cortex and the corticospinal tract after acute spinal cord injury: a prospective longitudinal study.

Freund P, Weiskopf N, Ashburner J, Wolf K, Sutter R, Altmann DR, Friston K, Thompson A, Curt A.

Lancet Neurol. 2013 Sep;12(9):873-881. doi: 10.1016/S1474-4422(13)70146-7. Epub 2013 Jul 2. Erratum in: Lancet Neurol. 2013 Sep;12(9):846.

32.

Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration.

Kearney H, Rocca MA, Valsasina P, Balk L, Sastre-Garriga J, Reinhardt J, Ruggieri S, Rovira A, Stippich C, Kappos L, Sprenger T, Tortorella P, Rovaris M, Gasperini C, Montalban X, Geurts JJ, Polman CH, Barkhof F, Filippi M, Altmann DR, Ciccarelli O, Miller DH, Chard DT.

Mult Scler. 2014 Jan;20(1):72-80. doi: 10.1177/1352458513492245. Epub 2013 Jun 27.

33.

Improved MRI quantification of spinal cord atrophy in multiple sclerosis.

Kearney H, Yiannakas MC, Abdel-Aziz K, Wheeler-Kingshott CA, Altmann DR, Ciccarelli O, Miller DH.

J Magn Reson Imaging. 2014 Mar;39(3):617-23. doi: 10.1002/jmri.24194. Epub 2013 Apr 30.

PMID:
23633384
34.

Spatial variability and changes of metabolite concentrations in the cortico-spinal tract in multiple sclerosis using coronal CSI.

Tur C, Wheeler-Kingshott CA, Altmann DR, Miller DH, Thompson AJ, Ciccarelli O.

Hum Brain Mapp. 2014 Mar;35(3):993-1003. doi: 10.1002/hbm.22229. Epub 2012 Dec 26.

35.

ADvanced IMage Algebra (ADIMA): a novel method for depicting multiple sclerosis lesion heterogeneity, as demonstrated by quantitative MRI.

Yiannakas MC, Tozer DJ, Schmierer K, Chard DT, Anderson VM, Altmann DR, Miller DH, Wheeler-Kingshott CA.

Mult Scler. 2013 May;19(6):732-41. doi: 10.1177/1352458512462074. Epub 2012 Oct 4.

36.

Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis-Sormani et al., Neurology 77, 2011.

Altmann DR.

Mult Scler Relat Disord. 2012 Jul;1(3):109-10. doi: 10.1016/j.msard.2012.02.003. Epub 2012 Mar 3. No abstract available.

PMID:
25877074
37.

Treating Atrial Fibrillation With Cryoballoon Technology.

Altmann DR, Knecht S, Sticherling C, Ammann P, Schaer B, Osswald S, Kühne M.

J Atr Fibrillation. 2012 Apr 14;4(6):486. doi: 10.4022/jafib.486. eCollection 2012 Apr-May. Review.

38.

Advances in imaging to support the development of novel therapies for multiple sclerosis.

Miller DH, Altmann DR, Chard DT.

Clin Pharmacol Ther. 2012 Apr;91(4):621-34. doi: 10.1038/clpt.2011.349. Epub 2012 Mar 7. Review.

PMID:
22398971
39.

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.

Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, Michell AW, Du MQ, Luan SL, Altmann DR, Thompson AJ, Compston A, Scott MA, Miller DH, Chandran S.

Lancet Neurol. 2012 Feb;11(2):150-6. doi: 10.1016/S1474-4422(11)70305-2. Epub 2012 Jan 10.

40.

Early factors associated with axonal loss after optic neuritis.

Henderson AP, Altmann DR, Trip SA, Miszkiel KA, Schlottmann PG, Jones SJ, Garway-Heath DF, Plant GT, Miller DH.

Ann Neurol. 2011 Dec;70(6):955-63. doi: 10.1002/ana.22554.

PMID:
22190367
41.

Longitudinal changes in magnetisation transfer ratio in secondary progressive multiple sclerosis: data from a randomised placebo controlled trial of lamotrigine.

Hayton T, Furby J, Smith KJ, Altmann DR, Brenner R, Chataway J, Hunter K, Tozer DJ, Miller DH, Kapoor R.

J Neurol. 2012 Mar;259(3):505-14. doi: 10.1007/s00415-011-6212-9. Epub 2011 Sep 9.

PMID:
21904901
42.

Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis.

Hayton T, Furby J, Smith KJ, Altmann DR, Brenner R, Chataway J, Hunter K, Tozer DJ, Miller DH, Kapoor R.

J Neurol. 2012 Feb;259(2):237-45. doi: 10.1007/s00415-011-6151-5. Epub 2011 Aug 24.

PMID:
21863390
43.

Grey matter damage and overall cognitive impairment in primary progressive multiple sclerosis.

Tur C, Penny S, Khaleeli Z, Altmann DR, Cipolotti L, Ron M, Thompson AJ, Ciccarelli O.

Mult Scler. 2011 Nov;17(11):1324-32. doi: 10.1177/1352458511410341. Epub 2011 Jul 29.

PMID:
21803874
44.

The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments.

Connick P, Kolappan M, Patani R, Scott MA, Crawley C, He XL, Richardson K, Barber K, Webber DJ, Wheeler-Kingshott CA, Tozer DJ, Samson RS, Thomas DL, Du MQ, Luan SL, Michell AW, Altmann DR, Thompson AJ, Miller DH, Compston A, Chandran S.

Trials. 2011 Mar 2;12:62. doi: 10.1186/1745-6215-12-62.

45.

Complementary roles of grey matter MTR and T2 lesions in predicting progression in early PPMS.

Tur C, Khaleeli Z, Ciccarelli O, Altmann DR, Cercignani M, Miller DH, Thompson AJ.

J Neurol Neurosurg Psychiatry. 2011 Apr;82(4):423-8. doi: 10.1136/jnnp.2010.209890. Epub 2010 Oct 25.

PMID:
20974648
46.

Clinical impact of screening for sleep related breathing disorders in atrial fibrillation.

Altmann DR, Ullmer E, Rickli H, Maeder MT, Sticherling C, Schaer BA, Osswald S, Ammann P.

Int J Cardiol. 2012 Feb 9;154(3):256-8. doi: 10.1016/j.ijcard.2010.09.034. Epub 2010 Oct 13.

PMID:
20947193
47.

Cervical cord and brain grey matter atrophy independently associate with long-term MS disability.

Bonati U, Fisniku LK, Altmann DR, Yiannakas MC, Furby J, Thompson AJ, Miller DH, Chard DT.

J Neurol Neurosurg Psychiatry. 2011 Apr;82(4):471-2. doi: 10.1136/jnnp.2010.205021. Epub 2010 Aug 14. No abstract available.

PMID:
20710012
48.

Hippocampal atrophy in relapsing-remitting and primary progressive MS: a comparative study.

Anderson VM, Fisniku LK, Khaleeli Z, Summers MM, Penny SA, Altmann DR, Thompson AJ, Ron MA, Miller DH.

Mult Scler. 2010 Sep;16(9):1083-90. doi: 10.1177/1352458510374893. Epub 2010 Jul 14.

PMID:
20630904
49.

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.

Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DR, Brenner R, Chataway J, Hughes RA, Miller DH.

Lancet Neurol. 2010 Jul;9(7):681-8. doi: 10.1016/S1474-4422(10)70131-9. Epub 2010 Jun 8.

PMID:
20621711
50.

A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials.

Henderson AP, Altmann DR, Trip AS, Kallis C, Jones SJ, Schlottmann PG, Garway-Heath DF, Plant GT, Miller DH.

Brain. 2010 Sep;133(9):2592-602. doi: 10.1093/brain/awq146. Epub 2010 Jun 20.

PMID:
20566483

Supplemental Content

Loading ...
Support Center